fbpx

Bausch + Lomb Responds to Rumors of a Potential Sale

Bausch + Lomb

Bausch + Lomb Corporation issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):

“The Bausch + Lomb Board of Directors authorized management and its advisors to explore a potential sale, which is one of several options being explored to complete a full separation from Bausch Health Companies Inc. That process is ongoing, and there can be no assurance that it will result in a transaction.

“While the company normally would not comment on deal negotiations, CIRO requested confirmation of a potential sale process given stock volatility often associated with market rumors. Bausch + Lomb does not intend to provide additional detail until further disclosure is appropriate or necessary.”

Bausch + Lomb is traded on both the New York Stock Exchange and Toronto Stock Exchange.

Source: Bausch + Lomb

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!

OneSight EssilorLuxottica Foundation Joins Forces with WHO to Advance Global Vision Care Under WHO SPECS 2030 Initiative

Onesight Essilorluxottica logo et SPECS 30

The OneSight EssilorLuxottica Foundation is proud to announce its collaboration with the World Health Organization (WHO) as a global collaborating partner on the WHO’s SPECS 2030 initiative.

The SPECS initiative builds on the world’s first-ever global target to increase effective refractive error coverage by 40% by 2030, which was endorsed by WHO Member States in 2021 at the World Health Assembly.

This collaboration between WHO and the Foundation represents a significant step forward in addressing refractive error, preventing myopia, and improving access to vision care worldwide, particularly in low-resource settings.

The collaboration will focus on knowledge sharing, technical input, and data provision to scale impactful solutions and ensure the effective implementation of United Nations’ ‘Vision for Everyone’ resolution. By leveraging their respective expertise, WHO and the Foundation aim to make sustainable vision care accessible to millions, improving health outcomes and social inclusion.

Dr Jérôme Salomon, Assistant Director-General, Universal Health Coverage, Communicable and Noncommunicable Diseases, WHO, emphasized the importance of collaborative action in achieving global eye health targets: “Vision care is not just a health priority – it is a social and economic imperative. The SPECS 2030 initiative, which underpins the UN ‘Vision for Everyone’ resolution, reminds us that effective collaboration can amplify impact, delivering tangible results for communities worldwide.

The WHO SPECS 2030 initiative accelerates global eye health efforts by focusing on five key pillars: Services, improving access to refractive services; Personnel, building the capacity of eye care professionals; Education, promoting public awareness about eye health; Cost, reducing the cost of eyeglasses and services; and Surveillance, strengthening data collection and research.

Across these areas, the Foundation will provide technical input, share best practices, and contribute data to inform WHO’s initiatives in alignment with the global eye care target of effective refractive error coverage.

Anurag Hans, Head of Mission at EssilorLuxottica and President of the OneSight EssilorLuxottica Foundation, highlighted the transformative potential of the collaboration: “Uncorrected poor vision affects 2.7 billion people worldwide, posing a significant global challenge. As a result of the Foundation’s efforts, 961 million people in some of the most remote communities now have access to vision care services within a day’s travel, and 84 million pairs of eyeglasses have been provided to those in need. However, achieving the Foundation’s ambition of eliminating uncorrected poor vision in a generation will require collaborations that amplify impact. By uniting WHO’s leadership in public health with our expertise in delivering innovative, on-the-ground solutions, we believe we can create a multiplier effect to extend vision care to even the most underserved regions. Together, we have the power to transform lives and uplift entire communities.

This collaboration reflects a shared commitment to improving lives through better vision and advancing progress toward Sustainable Development Goals, especially in health, education, and economic participation.

Click HERE for the press release.

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!

Optics 2025 Design Contest: See Beyond & Reveal!

Silmo Optical Design Contest 2025
Silmo Paris concours design optique

SILMO Paris, a key event in the optics and eyewear sector since 1967, is inviting design students to take up a unique challenge with the 4th edition of the Optical Design Contest.

SILMO is affirming its commitment to promoting expertise, supporting the industry and stimulating innovation through the Optical Design Contest.

A real springboard for tomorrow’s talent, this contest offers students from design schools all over the world the opportunity to go beyond the boundaries of innovation and explore the countless possibilities of design in the world of optics.

It’s an inspiring challenge that will reveal their vision of the future and inspire them to become active players in a constantly evolving industry!

THEME OF THE OPTICAL DESIGN 2025 CONTEST: Superhero glasses!

This year, the competition explores the potential of eyewear to transcend its simple function. Participants will have to design innovative frames capable of :

  • enhance vision and broaden our perception of the world
  • transform vision and the environment around them
  • redefine eyewear as a powerful technology, far beyond
  • a simple health accessory  

Through bold designs, the creations will have to go beyond their practical function to become instruments of transformation, elevation and reinvention of the view and the world.

Silmo concours design optique Michel Penneman, Président du Jury

Michel Penneman, President of the Jury

Internationally renowned Belgian designer and interior architect Michel Penneman is renowned for his innovative hotel renovations and his mastery of architectural narrative and colour.

Since his first projects in the 1990s, he has adopted an eclectic, conceptual approach, marked by a particular interest in light, transparency and adapting to the spirit of the place.

TERMS AND CONDITIONS OF ENTRY

  The contest is open to students enrolled in the 3rd, 4th or 5th year of a design course.

  Projects, submitted individually or as part of a team, must be submitted by 16 June 2025 on the dedicated platform.

EVALUATION CRITERIA

    Designs will be judged on their innovation, functional relevance, responsible commitment and technical feasibility.

  The finalists will be announced in July 2025 and prototypes will be exhibited at SILMO Paris 2025.

A PRESTIGIOUS PRIZE

 In addition to the recognition that comes with success, the winner will receive a prize of €10,000, divided equally between him or herself and his or her school. The winning project will be presented at SILMO Paris 2026.

KEY DATES

JUNE 16 – Closing date for entries

JULY – Nominees announcement

SEPTEMBER 26 – Prize Ceremony at the show

For more information : ibeuzen@silmo.fr

Click HERE for the press release.

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!

Kaleos Men: The Technical Era

Voila November-December 2024 Lanctôt Optical Kaleos Danforth

Kaleos is introducing this season Danforth, a rectangular aviator-style optical frame combining a thick titanium front and a high-density acetate trim. Showing a groundbreaking fusion of modernity, technical innovation and unparalleled quality, this model is setting new and higher standards in men’s eyewear.

Distributed by Lanctôt: www.rlanctot.com

About Lanctôt:

Lanctôt Ltée is excited to be celebrating its 65th Anniversary with over 5000 customers and partners! Since 1953 Lanctôt Ltée has been a Canadian based, family-run business that specializes in the distribution and production of premium sporting goods, apparel and eyewear. Our distribution and design expertise combined with our passion for sports is the foundation of our success.

Lanctôt offers 3 distinct categories: Sports Equipment, Apparel and Optical. Lanctôt’s brands fall into 7 divisions: Ski, Bike, Golf, Outerwear, Team Sports, Fashion and Eyewear. 

Want to see more like this article? Click here to subscribe to our FREE print magazines and e- newsletters!

Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

Bausch + Lomb

Bausch + Lomb Corporation announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants and bolsters Bausch + Lomb’s glaucoma portfolio, which features pharmaceutical and surgical approaches.

“Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address the evolving needs of their patients,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47% from 2020 to 2040.”1

Compared to other glaucoma surgery techniques, MIGS offers a safe and effective approach to lowering intraocular pressure with faster recovery time.2 It can also often be performed in conjunction with cataract surgery, the most routinely performed surgery in the world.3 More than 19% of patients who need cataract surgery also have glaucoma or ocular hypertension4; cataract surgery provides an optimal opportunity for concurrent glaucoma treatment.

“ELIOS provides a tissue-friendly, precision non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma. The synergy between cataract surgery and MIGS can help ophthalmologists provide streamlined care and improve patient quality of life.”

Professor Ike K. Ahmed, MD, University of Toronto and Moran Eye Center

“Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help change the treatment paradigm for the estimated 80 million people worldwide living with glaucoma,” said Elliot Friedman, former Elios Vision chairman and CEO. “The goal is to make combining cataract and glaucoma treatment the new standard of care, and that’s even more attainable given Bausch + Lomb’s presence in nearly 100 countries.”

The ELIOS technology, which is CE marked, is currently marketed and sold in the European Union. Elios Vision is in the process of pursuing U.S. Food and Drug Administration approval for the product.

Click here for a video demonstration of how ELIOS works.

Leerink Partners served as exclusive financial advisor to Elios Vision and Wilson Sonsini Goodrich & Rosati, Professional Corporation served as legal advisor.

Source: Bausch + Lomb

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!

Featured Posts

Fighting Blindness Canada

First Patients Dosed in Gene Therapy Trial for USH1B

AAVantgarde Bio, an Italy-based biotechnology company announced that the first patient has been dosed in their Phase ½ clinical trial. This trial will test the safety of a new gene therapy (AAVB-081) for Usher Syndrome Type.

Learn More
Voila November-December 2024 Gigi Studios Isotta

GIGI STUDIOS’ ISOTTA: Timeless Elegance Meets Modern Craftsmanship

Introducing ISOTTA from our VANGUARD collection: a perfect blend of timeless elegance and modern craftsmanship.

Read more
Vision Expo new logo

Vision Expo East to Debut New Elevated Experiences and Events in Orlando

Vision Expo East is set to transform and inspire the optical industry with a reimagined show floor and enhanced programming at its inaugural Orlando edition.

Read more
Transitions Innovation awards 2025- logo

Transitions Optical Announces 2024 Transitions® Innovation Awards Finalists

Transitions Optical has unveiled the finalists for its annual Transitions® Innovation Awards program, which recognizes individuals and organizations from North America who have shown unparalleled commitment to implementing innovative programs and technologies over the past year.

Read more
Optical Women’s Association logo

The Optical Women’s Association Announces Global Connection Event at MIDO in Milan

The Optical Women’s Association (OWA) announces an OWA Global Event at MIDO in Milan, as expansion plans continue to reach out to women in the optical industry internationally.

Read more
Fighting Blindness Canada

First Patients Dosed in Gene Therapy Trial for USH1B

AAVantgarde Bio, an Italy-based biotechnology company announced that the first patient has been dosed in their Phase ½ clinical trial. This trial will test the safety of a new gene therapy (AAVB-081) for Usher Syndrome Type.

Learn More
Voila November-December 2024 Gigi Studios Isotta

GIGI STUDIOS’ ISOTTA: Timeless Elegance Meets Modern Craftsmanship

Introducing ISOTTA from our VANGUARD collection: a perfect blend of timeless elegance and modern craftsmanship.

Read More
Vision Expo new logo

Vision Expo East to Debut New Elevated Experiences and Events in Orlando

Vision Expo East is set to transform and inspire the optical industry with a reimagined show floor and enhanced programming at its inaugural Orlando edition.

Read More
Transitions Innovation awards 2025- logo

Transitions Optical Announces 2024 Transitions® Innovation Awards Finalists

Transitions Optical has unveiled the finalists for its annual Transitions® Innovation Awards program, which recognizes individuals and organizations from North America who have shown unparalleled commitment to implementing innovative programs and technologies over the past year.

Read More
Optical Women’s Association logo

The Optical Women’s Association Announces Global Connection Event at MIDO in Milan

The Optical Women’s Association (OWA) announces an OWA Global Event at MIDO in Milan, as expansion plans continue to reach out to women in the optical industry internationally.

Read More
Fighting Blindness Canada

First Patients Dosed in Gene Therapy Trial for USH1B

AAVantgarde Bio, an Italy-based biotechnology company announced that the first patient has been dosed in their Phase ½ clinical trial. This trial will test the safety of a new gene therapy (AAVB-081) for Usher Syndrome Type.

Learn More
Voila November-December 2024 Gigi Studios Isotta

GIGI STUDIOS’ ISOTTA: Timeless Elegance Meets Modern Craftsmanship

Introducing ISOTTA from our VANGUARD collection: a perfect blend of timeless elegance and modern craftsmanship.

Read more
Vision Expo new logo

Vision Expo East to Debut New Elevated Experiences and Events in Orlando

Vision Expo East is set to transform and inspire the optical industry with a reimagined show floor and enhanced programming at its inaugural Orlando edition.

Read more
Transitions Innovation awards 2025- logo

Transitions Optical Announces 2024 Transitions® Innovation Awards Finalists

Transitions Optical has unveiled the finalists for its annual Transitions® Innovation Awards program, which recognizes individuals and organizations from North America who have shown unparalleled commitment to implementing innovative programs and technologies over the past year.

Read more
Optical Women’s Association logo

The Optical Women’s Association Announces Global Connection Event at MIDO in Milan

The Optical Women’s Association (OWA) announces an OWA Global Event at MIDO in Milan, as expansion plans continue to reach out to women in the optical industry internationally.

Read more
Fighting Blindness Canada

First Patients Dosed in Gene Therapy Trial for USH1B

AAVantgarde Bio, an Italy-based biotechnology company announced that the first patient has been dosed in their Phase ½ clinical trial. This trial will test the safety of a new gene therapy (AAVB-081) for Usher Syndrome Type.

Learn More
Voila November-December 2024 Gigi Studios Isotta

GIGI STUDIOS’ ISOTTA: Timeless Elegance Meets Modern Craftsmanship

Introducing ISOTTA from our VANGUARD collection: a perfect blend of timeless elegance and modern craftsmanship.

Read more
Vision Expo new logo

Vision Expo East to Debut New Elevated Experiences and Events in Orlando

Vision Expo East is set to transform and inspire the optical industry with a reimagined show floor and enhanced programming at its inaugural Orlando edition.

Read more
Transitions Innovation awards 2025- logo

Transitions Optical Announces 2024 Transitions® Innovation Awards Finalists

Transitions Optical has unveiled the finalists for its annual Transitions® Innovation Awards program, which recognizes individuals and organizations from North America who have shown unparalleled commitment to implementing innovative programs and technologies over the past year.

Read more
Optical Women’s Association logo

The Optical Women’s Association Announces Global Connection Event at MIDO in Milan

The Optical Women’s Association (OWA) announces an OWA Global Event at MIDO in Milan, as expansion plans continue to reach out to women in the optical industry internationally.

Read more